U.S. market Closed. Opens in 2 days 4 hours 26 minutes

CRIS | Curis, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.07 - 3.22
52 Week Range 2.8600 - 17.49
Beta 3.28
Implied Volatility 546.23%
IV Rank 33.78%
Day's Volume 19,225
Average Volume 113,464
Shares Outstanding 8,466,960
Market Cap 26,247,576
Sector Healthcare
Industry Biotechnology
IPO Date 2000-08-01
Valuation
Profitability
Growth
Health
P/E Ratio -0.40
Forward P/E Ratio -3.86
EPS -7.77
1YR Price Target 17.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 49
Country USA
Website CRIS
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
CRIS's peers: ALRN, ARTL, HSTO, TMBR, XFOR, MREO, INZY, TERN, LPTX, DAWN, PDSB, ADAP, PIRS, AFMD, CRVS, APTO
*Chart delayed
Analyzing fundamentals for CRIS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see CRIS Fundamentals page.

Watching at CRIS technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on CRIS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙